Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immunogenicity and safety of yellow fever vaccine in HIV-1-infected patients.
Colin de Verdiere N, Durier C, Samri A, Meiffredy V, Launay O, Matheron S, Mercier-Delarue S, Even S, Aboulker JP, Molina JM, Autran B, Simon F; ANRS EP46 NOVAA Group. Colin de Verdiere N, et al. Among authors: launay o. AIDS. 2018 Oct 23;32(16):2291-2299. doi: 10.1097/QAD.0000000000001963. AIDS. 2018. PMID: 30096071
Nevirapine or lamivudine plus stavudine and indinavir: examples of 2-class versus 3-class regimens for the treatment of human immunodeficiency virus type 1.
Launay O, Gérard L, Morand-Joubert L, Flandre P, Guiramand-Hugon S, Joly V, Peytavin G, Certain A, Lévy C, Rivet S, Jacomet C, Aboulker JP, Yéni P; Agence Nationale de Recherches sur le SIDA (ANRS) 081 Study Group. Launay O, et al. Clin Infect Dis. 2002 Nov 1;35(9):1096-105. doi: 10.1086/342694. Epub 2002 Oct 15. Clin Infect Dis. 2002. PMID: 12384844 Clinical Trial.
Contribution of cellular HIV-1 DNA quantification to the efficacy analysis of antiretroviral therapy: a randomized comparison of 2 regimens, including 3 drugs from 2 or 3 classes (TRIANON, ANRS 081).
Morand-Joubert L, Marcellin F, Launay O, Guiramand-Hugon S, Gérard L, Yeni P, Aboulker JP; Agence Nationale de Recherches sur le SIDA 081 Study Group. Morand-Joubert L, et al. Among authors: launay o. J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):268-76. J Acquir Immune Defic Syndr. 2005. PMID: 15735443 Clinical Trial.
Cellular immune responses induced with dose-sparing intradermal administration of HIV vaccine to HIV-uninfected volunteers in the ANRS VAC16 trial.
Launay O, Durier C, Desaint C, Silbermann B, Jackson A, Pialoux G, Bonnet B, Poizot-Martin I, Gonzalez-Canali G, Cuzin L, Figuereido S, Surenaud M, Ben Hamouda N, Gahery H, Choppin J, Salmon D, Guérin C, Bourgault Villada I, Guillet JG; ANRS VAC16 Study Group. Launay O, et al. PLoS One. 2007 Aug 22;2(8):e725. doi: 10.1371/journal.pone.0000725. PLoS One. 2007. PMID: 17712402 Free PMC article. Clinical Trial.
Immunogenicity and safety of an HIV-1 lipopeptide vaccine in healthy adults: a phase 2 placebo-controlled ANRS trial.
Salmon-Céron D, Durier C, Desaint C, Cuzin L, Surenaud M, Hamouda NB, Lelièvre JD, Bonnet B, Pialoux G, Poizot-Martin I, Aboulker JP, Lévy Y, Launay O; ANRS VAC18 trial group. Salmon-Céron D, et al. Among authors: launay o. AIDS. 2010 Sep 10;24(14):2211-23. doi: 10.1097/QAD.0b013e32833ce566. AIDS. 2010. PMID: 20625264 Clinical Trial.
Impact of individual antiretroviral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4.
Lang S, Mary-Krause M, Cotte L, Gilquin J, Partisani M, Simon A, Boccara F, Costagliola D; Clinical Epidemiology Group of the French Hospital Database on HIV. Lang S, et al. Arch Intern Med. 2010 Jul 26;170(14):1228-38. doi: 10.1001/archinternmed.2010.197. Arch Intern Med. 2010. PMID: 20660842
484 results